Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2024

Mar 5, 2024

31100_dirs_2024-03-04_ccc91467-2606-4cca-9884-b5e022b4ad7d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-02-29

Reporting Person: Wassil Jim (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-02-29 Common Stock A 20000 Acquired 223852 Direct
2024-03-01 Common Stock S 1017 $73.078 Disposed 222835 Direct
2024-03-01 Common Stock S 1220 $73.624 Disposed 221615 Direct
2024-03-01 Common Stock S 763 $74.695 Disposed 220852 Direct
2024-03-02 Common Stock F 2178 $71.55 Disposed 218674 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-29 Stock Option (right to buy) $73.82 A 90000 Acquired 2034-02-28 Common Stock (90000) Direct

Footnotes

F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.39 to $73.355. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $74.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.46 to $75.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F6: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.

F7: 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.